.jpg?format=webp&quality=80&width=3840)
Despite effective antiretroviral therapy (ART), HIV-infected individuals worldwide remain at significant risk of respiratory infections and non-communicable diseases. Severe disease from SARS-CoV-2 is associated with a hyperinflammatory phenotype that manifests in the lungs as pneumonia and, in some cases, can lead to acute respiratory failure. Progression to severe COVID-19 is associated with comorbid diseases such as obesity, diabetes mellitus, and cardiovascular disease. However, data concerning the associated risks of HIV coinfection are still conflicting, with large population studies demonstrating poorer outcomes whilst smaller, case-controlled studies show better results. Furthermore, underlying immunopathological processes within the lungs and elsewhere, including interactions with other opportunistic infections (OI), remain largely undefined. Nonetheless, new and repurposed anti-viral therapies and vaccines that have been developed are safe to use in this population, and anti-inflammatory agents are recommended with the caveat that the coexistence of opportunistic infections is considered and excluded. Finally, HIV-infected patients rely on good ART adherence practices to maintain HIV viral suppression. Unfortunately, some of these practices were disrupted during the COVID-19 pandemic, putting these patients at additional risk for acute and long-term adverse outcomes.
Like
Save
Share